ACS Bio & Med Chem AuBiochemistryPeer-reviewed journal article
1,2,4-Triazole-based first-in-class non-nucleoside inhibitors of bacterial enzyme MraY
Tomayo I. BeridaiD, Tzu‐Yu HuangiD, Stefanie C. Weck, Marcel Lutz, Samuel R. McKeeiD, Nathalie Kagerah, Destinee L. ManningiD, Mohamed E. Jahan, Sushil K. MishraiD, Jennifer E. HerrmanniD, Rolf MülleriD, Robert J. DoerkseniD, Christina L. StallingsiD, Christian DuchoiD, Sudeshna RoyiD
Abstract
MraY, a bacterial enzyme crucial for the synthesis of peptidoglycans, represents a promising yet underexplored target for the development of effective antibacterial agents. Nature has provided several classes of nucleoside inhibitors of MraY and scientists have modified these structures further to obtain natural product-like inhibitors of MraY. The natural products and their synthetic analogs suffer from non-optimal in vivo efficacy, and the synthetic complexity of the structures renders the synthesis and structure-activity relationship (SAR) studies of these molecules particularly challenging. In this study, we present our findings on the discovery of first-in-class 1,2,4-triazole-based MraY inhibitors that are not nucleoside-derived. A series of 1,2,4-triazole analogous were identified by a structure-activity-relationship (SAR) study using a structure-based drug design strategy. Compound 1, with an IC50 of 171 {micro}M against MraY from Staphylococcus aureus (MraYSA), was optimized to compound 12a, exhibiting an IC50 of 25 {micro}M. Molecular docking studies against MraYSA provided insights into these compounds binding interactions and activity. Furthermore, screening against the ESKAPE bacterial panel was also conducted, through which we discovered compounds demonstrating broad-spectrum antibacterial activity against E. faecium, methicillin-resistant S. aureus (MRSA), vancomycin-resistant Enterococci (VRE) strains and Mycobacterium tuberculosis. The novel, first-in-class non-nucleoside inhibitors of MraY highlighted in this work provide a strong proof-of-concept of how to leverage structural information of the protein to develop future antibacterial agents targeting MraY. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=168 SRC="FIGDIR/small/635793v1_ufig1.gif" ALT="Figure 1"> View larger version (54K): org.highwire.dtl.DTLVardef@14b1f84org.highwire.dtl.DTLVardef@1024f45org.highwire.dtl.DTLVardef@a246d0org.highwire.dtl.DTLVardef@1d70e52_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- organism: mouse
- organism: rat
- assay: proteomics
- research focus: drug response / drug discovery
- approach: deep learning
- approach: statistical model
- Citations
- 2
- FWCI
- 0.60
- Field percentile
- top 41%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Design of a novel DNA Gyrase B inhibitor with a rhodanine scaffold: in silico and in vitro approaches
A. Pudipeddi, S. Vasudevan, … A. P. Solomon·bioRxiv·Jan 24, 2021
- Discovery, Synthesis, and Optimization of 1,2,4-Triazolyl Pyridines Targeting Mycobacterium tuberculosis
S. Roy, T. Berida, … C. L. Stallings·bioRxiv·Nov 14, 2022
- Discovery of novel 1,4-dicarbonylthiosemicarbazides as DNA gyrase inhibitors for the treatment of MRSA infection
Gao Zhang, Jiaxin Liang, … Song Wu·European Journal of Medicinal ChemistryPeer-reviewed·Sep 27, 2024
- Low-cost drug discovery with engineered E. coli reveals an anti-mycobacterial activity of benazepril
Nadine Bongaerts, Zainab Edoo, … Edwin H. Wintermute·bioRxiv·Mar 26, 2021
- Structure-guided enhancement of selectivity of chemical probe inhibitors targeting bacterial seryl-tRNA synthetase
R. Cain, R. Salimaraj, … D. I. Roper·bioRxiv·Mar 22, 2019
- Deep reinforcement learning-driven discovery of a MsbA-targeted small-molecule antibiotic for the treatment of Acinetobacter baumannii infection
Lei Wang, Baixin Jing, … Jie Xia·bioRxiv·Sep 15, 2026